Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $1.1 in the prior trading day, Fate Therapeutics Inc (NASDAQ: FATE) closed at $1.04, down -5.45%. In other words, the price has decreased by -$5.45 from its previous closing price. On the day, 3.75 million shares were traded. FATE stock price reached its highest trading level at $1.095 during the session, while it also had its lowest trading level at $1.03.
Ratios:
Our goal is to gain a better understanding of FATE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.81 and its Current Ratio is at 8.81. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.27.
On June 17, 2024, Piper Sandler Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $4 to $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 06 ’25 when Wolchko J Scott bought 113,178 shares for $0.93 per share.
Bressi Jerome Charles sold 5,980 shares of FATE for $9,269 on Jan 10 ’25. The insider now owns 270,203 shares after completing the transaction at $1.55 per share. On Jan 10 ’25, another insider, TAHL CINDY, who serves as the insider of the company, sold 5,654 shares for $1.55 each. As a result, the insider received 8,764 and left with 336,707 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FATE now has a Market Capitalization of 119218312 and an Enterprise Value of -37874656. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.94 while its Price-to-Book (P/B) ratio in mrq is 0.41. Its current Enterprise Value per Revenue stands at -2.84 whereas that against EBITDA is 0.225.
Stock Price History:
The Beta on a monthly basis for FATE is 2.20, which has changed by -0.68098164 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, FATE has reached a high of $5.92, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -15.04%, while the 200-Day Moving Average is calculated to be -42.54%.
Shares Statistics:
The stock has traded on average 2.08M shares per day over the past 3-months and 1848220 shares per day over the last 10 days, according to various share statistics. A total of 114.60M shares are outstanding, with a floating share count of 107.09M. Insiders hold about 6.58% of the company’s shares, while institutions hold 84.23% stake in the company. Shares short for FATE as of 1749772800 were 9512319 with a Short Ratio of 4.58, compared to 1747267200 on 12870954. Therefore, it implies a Short% of Shares Outstanding of 9512319 and a Short% of Float of 9.4799995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Fate Therapeutics Inc (FATE) is currently in the spotlight, with 10.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.23 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.0 and -$1.38 for the fiscal current year, implying an average EPS of -$1.24. EPS for the following year is -$1.15, with 10.0 analysts recommending between -$0.73 and -$1.53.
Revenue Estimates
A total of 9 analysts have provided revenue estimates for FATE’s current fiscal year. The highest revenue estimate was $13.6M, while the lowest revenue estimate was $1.63M, resulting in an average revenue estimate of $5.33M. In the same quarter a year ago, actual revenue was $13.63M
